DDMAC deems AzaSite ad misleading
May 13 2011
A four-page journal ad for Inspire Pharmaceuticals' AzaSite has been reviewed and determined as misleading by FDA's DDMAC.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.